|
[1]GUPTA S, JEN J, KOLZ K, et al.Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia[J].Br J Clin Pharmacol, 2007, 63 (3) :292-299.
|
|
[2]SULKOWSKI MS, COOPER C, HUNYADY B, et al.Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C[J].Nat Rev Gastroenterol Hepatol, 2011, 8 (4) :212-223.
|
|
[3]MCHUTCHISON JG, LAWITZ EJ, SHIFFMAN ML, et al.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection[J].N Engl J Med, 2009, 361 (6) :580-593.
|
|
[4]ROOMER R, HANSEN BE, JANSSEN HL, et al.Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C[J].J Hepatol, 2010, 53 (3) :455-459.
|
|
[5]LAU GK, PIRATVISUTH T, LUO KX, et al.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005, 352 (26) :2682-2695.
|
|
[6]GUYATT GH, OXMAN AD, VIST GE, et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ, 2008, 336 (7650) :924-926.
|
|
[7]KIRKWOOD JM, BENDER C, AGARWALA S, et al.Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy[J].J Clin Oncol, 2002, 20 (17) :3703-3718.
|
|
[8]HAUSCHILD A, GOGAS H, TARHINI A, et al.Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma:expert opinion[J].Cancer, 2008, 112 (5) :982-994.
|
|
[9]NISSEN C, SPECK B, EMDI G, et al.Toxicity of human leucocyte interferon preparations in human bone-marrow cultures[J].Lancet, 1977, 1 (8004) :203-204.
|
|
[10]GANSER A, CARLO-STELLA C, GREHER J, et al.Effect of recombinant interferons alpha and gamma on human bone marrowderived megakaryocytic progenitor cells[J].Blood, 1987, 70 (4) :1173-1179.
|
|
[11]LIU YL, DU XF, CHEN XY, et al.Bone marrow suppression or active proliferation?An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C[J].Scand J Infect Dis, 2013, 45 (12) :939-943.
|
|
[12]WADA M, MARUSAWA H, YAMADA R, et al.Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients[J].J Viral Hepat, 2009, 16 (6) :388-396.
|
|
[13]ROTMAN Y, KATZ L, COHEN M, et al.Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C[J].J Viral Hepat, 2009, 16 (5) :340-345.
|
|
[14]FRIED MW.Side effects of therapy for hepatitis C and their management[J].Hepatology, 2002, 36 (5 Suppl 1) :s237-s244.
|
|
[15]MANNS MP, MCHUTCHISON JG, GORDON SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J].Lancet, 2001, 358 (9286) :958-965.
|
|
[16]GLUE P, ROUZIER-PANIS R, RAFFANEL C, et al.A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C[J].Hepatology, 2000, 32 (3) :647-653.
|
|
[17]SOZA A, EVERHART JE, GHANY MG, et al.Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C[J].Hepatology, 2002, 36 (5) :1273-1279.
|
|
[18]FRIED MW, SHIFFMAN ML, REDDY KR, et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.
|
|
[19]COOPER CL, AL-BEDWAWI S, LEE C, et al.Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia[J].Clin Infect Dis, 2006, 42 (12) :1674-1678.
|
|
[20]JUAREZ-NAVARRO A, VERA-de-LEóN L, NAVARRO JM, et al.Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection[J].Methods Find Exp Clin Pharmacol, 2005, 27 (5) :317-322.
|
|
[21]CURRY MP, AFDHAL NH.Use of growth factors with antiviral therapy for chronic hepatitis C[J].Clin Liver Dis, 2005, 9 (3) :439-451.
|
|
[22]PUOTI M, BABUDIERI S, REZZA G, et al.Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C:a side effect of pegylation?[J].Antivir Ther, 2004, 9 (4) :627-630.
|
|
[23]KOIRALA J, GANDOTRA SD, RAO S, et al.Granulocyte colonystimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy[J].J Viral Hepat, 2007, 14 (11) :782-787.
|
|
[24]GONZALEZ SA, JACOBSON IM.The role of hematopoietic growth factors in special populations with chronic hepatitis C:patients with HIV coinfection, end-stage renal disease, or liver transplantation[J].Cleve Clin J Med, 2004, 71 (Suppl 3) :s22-s26.
|
|
[25]GOLIA P, TALAL AH, JACOBSON IM, et al.A preliminary study of growth factors versus dose reduction for peginterferon alfa-2b and ribavirin associated neutropenia and anemia in HIV/HCV coinfected patients[J].Gastroenterology, 2003, 124 (Suppl 1) :a766.
|
|
[26]GMUR J, BURGER J, SCHANZ U, et al.Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia[J].Lancet, 1991, 338 (8777) :1223-1226.
|
|
[27]ZDILAR D, FRANCO-BRONSON K, BUCHLER N, et al.Hepatitis C, interferon alfa, and depression[J].Hepatology, 2000, 31 (6) :1207-1211.
|
|
[28]FONTANA RJ.Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C[J].Dig Dis, 2000, 18 (3) :107-116.
|
|
[29]BONACCORSO S, MARINO V, PUZELLA A, et al.Increased depressive ratings in patients with hepatitis C receiving interferon-alphabased immunotherapy are related to interferon-alpha-induced changes in the serotonergic system[J].J Clin Psychopharmacol, 2002, 22 (1) :86-90.
|
|
[30]LOFTIS JM, HUCKANS M, RUIMY S, et al.Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha[J].Neurosci Lett, 2008, 430 (3) :264-268.
|
|
[31]RAISON CL, DEMETRASHVILI M, CAPURON L, et al.Neuropsychiatric adverse effects of interferon-alpha:recognition and management[J].CNS Drugs, 2005, 19 (2) :105-123.
|
|
[32]CONRAD B.Potential mechanisms of interferon-alpha induced autoimmunity[J].Autoimmunity, 2003, 36 (8) :519-523.
|
|
[33]MANDAC JC, CHAUDHRY S, SHERMAN KE, et al.The clinical and physiological spectrum of interferon-alpha induced thyroiditis:toward a new classification[J].Hepatology, 2006, 43 (4) :661-672.
|
|
[34]WATANABE U, HASHIMOTO E, HISAMITSU T, et al.The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C[J].Am J Gastroenterol, 1994, 89 (3) :399-403.
|
|
[35]MAZZIOTTI G, SORVILLO F, STORNAIUOLO G, et al.Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis:a prospective study[J].J Endocrinol Invest, 2002, 25 (7) :624-630.
|
|
[36]OPPENHEIM Y, BAN Y, TOMER Y.Interferon induced Autoimmune Thyroid Disease (AITD) :a model for human autoimmunity[J].Autoimmun Rev, 2004, 3 (5) :388-393.
|
|
[37]WONG V, FU AX, GEORGE J, et al.Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis[J].Clin Endocrinol (Oxf) , 2002, 56 (6) :793-798.
|
|
[38]CARELLA C, MAZZIOTTI G, MORISCO F, et al.Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment[J].J Clin Endocrinol Metab, 2001, 86 (5) :1925-1929.
|
|
[39]CHEN HZ.Practice of internal medicine[M].11th ed.Beijing:People's Medical Publishing House, 2011:1143-1159. (in Chinese) 陈灏珠.实用内科学[M].11版.北京:人民卫生出版社, 2011:1143-1159.
|
|
[40]FABRIS P, FLOREANI A, TOSITTI G, et al.Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy[J].Aliment Pharmacol Ther, 2003, 18 (6) :549-558.
|
|
[41]SCHREUDER TC, GELDERBLOM HC, WEEGINK CJ, et al.High incidence of type 1 diabetes mellitus during or shortlyafter treatment with pegylated interferon alpha for chronic hepatitis C virus infection[J].Liver Int, 2008, 28 (1) :39-46.
|
|
[42]KARIM A, AHMED S, KHAN A, et al.Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection[J].Am J Med Sci, 2001, 322 (4) :233-235.
|
|
[43]SENE D, TOUITOU V, BODAGHI B, et al.Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C[J].World J Gastroenterol, 2007, 13 (22) :3137-3140.
|
|
[44]WIRTH S, PIEPER-BOUSTANI H, LANG T, et al.Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C[J].Hepatology, 2005, 41 (5) :1013-1018.
|
|
[45]TOSTI A, MISTIALI C, BARDAZZI F, et al.Telogen effluvium due to recombinant interferon alfa-2b[J].Dermatology, 1992, 184 (2) :124-125.
|
DownLoad: